rEVO Biologics Company Profile

10:31 EDT 30th August 2014 | BioPortfolio

rEVO Biologics is a rare disease company focused on developing and delivering first and next-generation therapeutics that are more cost effective to produce than traditional recombinant therapies. Through its proprietary rPRO Technology platform -- a scalable, transgenic, and cost-effective method of protein production-- rEVO Biologics is bringing safe and reliable therapeutic proteins to address critical medical needs. The company’s lead product, ATryn® Antithrombin (Recombinant), is the first and only plasma-free antithrombin concentrate. ATryn received FDA approval in 2009. The company has a number of products in its pipeline and in clinical trials in the areas of hematology, oncology, genetic disorders and autoimmune disease, and is actively seeking additional indications for its lead product.


News Articles [401 Associated News Articles listed on BioPortfolio]

LFB’s rEVO Biologics attempts IPO

Recombinant protein therapeutics developer rEVO Biologics Inc. filed for its initial public offering.

rEVO Biologics begins Phase III trial of preeclampsia drug ATryn

US-based commercial-stage biopharmaceutical firm rEVO Biologics has started PRESERVE-1 Phase III clinical trial of ATryn [antithrombin (Recombinant)] to treat preeclampsia in pregnant women during the...

rEVO files for IPO

rEVO Biologics Inc., a subsidiary of LFB S.A. (Les Ulis, France), filed to raise up to $74.8 million in an IPO on NASDAQ underwritten by Piper Jaffray; Guggenheim Securities; Roth Capital Partners; an...

rEVO biologics enrolls first patient in ATryn Phase III trial for preeclampsia

LFB Biotechnologies’ subsidiary rEVO Biologics has enrolled the first patient in its Phase III clinical trial of ATryn to treat preeclampsia.

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

rEVO Biologics Inc., a subsidiary of LFB SA, today announced the initiation of the Phase 3 clinical program for ATryn for the treatment of preeclampsia in pregnant women during the 24th to 28th week o...

rEVO Biologics proposes IPO

How is the post monoclonal antibodies (mAb) world going to develop in the future of biologics?

  As the pharma industry moves into the future of biologics production what challenges will they be facing? The field of biologics is currently on the brink of a new era of high tech drugs. These new...

Biologics lift for UK

Work has begun on a key new £38 million centre in Central Park, Darlington, which should increase the biologics capability of the UK. Due for completion in 2015, the National Biologics Manufacturing...

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Standardized cat pelt [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT PELT AP ACETONE PRECIPITATED

Standardized cat hair [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT HAIR AP Acetone Precipitated

Cinryze [ViroPharma Biologics]

These highlights do not include all the information needed to use CINRYZE™ safely and effectively. See full prescribing information for CINRYZE.CINRYZE™ (C1 Esterase Inhibitor [Human]) For Intrave...

PubMed Articles [91 Associated PubMed Articles listed on BioPortfolio]

When biologics should be used in systemic lupus erythematosus?

Recently, the use and evaluation of biologics increased in systemic lupus erythematosus (SLE). However, no international recommendation is available concerning the use of biologics with regards to the...

Demystifying the u.s. Food and drug administration: I. Understanding agency structure and function.

The U.S. Food and Drug Administration is the government agency responsible for oversight of the safety and efficacy of pharmaceuticals and devices, including biologics and devices that combine biologi...

Patch Test Results in Psoriasis Patients on Biologics.

The objective of this study was to determine the prevalence of positive patch tests in patients with psoriasis receiving biologics and whether these results differ from those of patients with psoriasi...

Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.

To study the factors associated with withdrawal of the and tumor necrosis factor alpha (anti-TNFα) biologics in the treatment of rheumatic diseases.

Assessment of the metabolism of therapeutic proteins and antibodies.

Introduction: In the last decade, our increased knowledge of factors governing the pharmacokinetics and metabolism of biologics (recombinant therapeutic proteins) has driven, and will continue to supp...

Clinical Trials [21 Associated Clinical Trials listed on BioPortfolio]

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health...

Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment

This study involves review and analysis of disease activity in patients with rheumatoid arthritis who where treated with either conventional DMARDs (Disease Modifying Antirheumatic Drugs)...

Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA)

Biologics are routinely used for the treatment of rheumatoid arthritis (RA). Adalimumab is a human monoclonal antibody that inhibit the Tumor Necrosis Factor alpha (TNF-alpha). Identificat...

Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis

The purpose of this study is to evaluate the safety, pharmacokinetics, and efficacy of various repeat-dose regimens of KB003 in subjects with active Rheumatoid Arthritis (RA) who have had...

Companies [190 Associated Companies listed on BioPortfolio]

rEVO Biologics

rEVO Biologics is a rare disease company focused on developing and delivering first and next-generation therapeutics that are more cost effective to produce than traditional recom...

rEVO Biologics Inc.

rEVO Biologics Inc. (www.revobiologics.com) is a commercial-stage biopharmaceutical company focused on the development and commercialization of specialty therapeutics to address...

rEVO Biologics, Inc.

rEVO Biologics, Inc. (www.revobiologics.com) is a commercial-stage biopharmaceutical company focused on the development and commercialization of specialty therapeutics to address...

MSD Biologics (UK) Limited

Avecia Biologics was acquired in February 2010 by MSD, the UK subsidiary of Merck & Co Inc, the world’s second largest pharmaceutical company. MSD Billingham is one of the world's leading contract...

Precision Biologics, Inc.

Founded in February 2012 and commencing business in late September 2012, Precision Biologics, Inc. is a clinical stage biotechnology corporation focused on developing therapeutic...

More Information about "rEVO Biologics" on BioPortfolio

We have published hundreds of rEVO Biologics news stories on BioPortfolio along with dozens of rEVO Biologics Clinical Trials and PubMed Articles about rEVO Biologics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of rEVO Biologics Companies in our database. You can also find out about relevant rEVO Biologics Drugs and Medications on this site too.

Search BioPortfolio:
Advertisement

Relevant Topic

Blood
Latest News Clinical Trials Research Drugs Reports Corporate
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record